TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06249828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MegaCarti^®
Description: MegaCarti® application after microfracture through athroscopic or incision surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery
Study: NCT05521113

Intervention type: BEHAVIORAL
Intervention: Home Rehabilitation Monitoring System
Description: The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.

Intervention type: BEHAVIORAL
Intervention: Health coaching calls
Description: 12 telephone-based health coaching calls over a 12-week period
Study: NCT04748536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL201104
Description: lyophilised powder for reconstitution for IV dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL201104
Description: lyophilised powder for reconstitution for IV dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for IRL201104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for IRL201104
Study: NCT04796675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Study: NCT05785065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day
Study: NCT05500079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist splint
Description: A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radiofrequency current
Description: Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.
Study: NCT05674409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family-Involved Treatment (B-FIT)
Description: Brief Family-Involved Treatment (B-FIT) is a manualized, 3-session intervention for Alcohol Use Disorder (AUD). Designed to be implemented in combination with any existing alcohol treatment program, the goals of B-FIT are to (1) increase reinforcement for AUD treatment engagement, (2) increase positive rewards from drinking reductions, and (3) decrease drinking cues by decreasing negative communication and increasing positive communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
Description: Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
Description: Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
Study: NCT05415514

Intervention type: OTHER
Group type: OTHER
Intervention: Instrumented assessment of muscle function
Description: During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
Study: NCT05805020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cellvizio
Description: During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
Study: NCT03585946

Intervention type: DRUG
Intervention: Site specific standard of care comparison
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.

Intervention type: DRUG
Intervention: Site specific standard of care comparison
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.

Intervention type: DRUG
Intervention: Site specific standard of care comparison
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.

Intervention type: DRUG
Intervention: Site specific standard of care comparison
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
Study: NCT06242938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early intensive antihypertensive treatment
Description: 1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.).
Study: NCT03825536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Methamphetamine
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For the oral methamphetamine treatment arm, an initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Methamphetamine
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For the oral methamphetamine treatment arm, an initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
Study: NCT05326126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary physiology
Description: To evaluate the association between microvascular disfunction and myocardial fibrosis identified per computed tomography among subjects undergoing TAVI for severe, symptomatic aortic stenosis.
Study: NCT05409755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivacy
Description: Vivacy and minoxidil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivacy
Description: Vivacy and minoxidil
Study: NCT03825536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For placebo treatment phase, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For placebo treatment phase, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
Study: NCT04793750

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cepheid GeneXpert HIV-1 Qual POC HIV VL test
Description: POC Nucleic acid-based test for HIV RNA.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DPP HIV-Syphilis test system
Description: POC Tests for antibodies to HIV 1/2 and Treponema pallidum.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DPP HIV-Syphilis test system
Description: POC Tests for antibodies to HIV 1/2 and Treponema pallidum.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OraQuick
Description: POC oral fluid swab test for HIV 1/2 antibodies.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick
Description: POC oral fluid swab test for HIV 1/2 antibodies.
Study: NCT05923645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (Hf rTMS)
Description: TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient
Study: NCT05702541

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfection system
Description: Commercially available cleaning and disinfection system for silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfection system
Description: Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
Study: NCT05409755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivacy
Description: Vivacy and minoxidil
Study: NCT05668299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrachFlush
Description: See detailed description previously entered.
Study: NCT04816864

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: extracardiac vagal nerve stimulation (ECANS) + EPS
Description: The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: extracardiac vagal nerve stimulation (ECANS) + EPS
Description: The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.
Study: NCT05515783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-RGD
Description: The dose will be 4-7mCi given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-RGD
Description: 68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
Study: NCT04859309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActiveHip+ mobile application
Description: The mobile application with the educational and multidisciplinary tele-rehabilitation program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care in a hip fracture
Description: The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
Study: NCT05591534

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Endorectal brachytherapy
Description: Endorectal brachytherapy : 30 Gy in 3 sessions of 10 Gy delivered weekly
Study: NCT05773625

Intervention type: DEVICE
Group type: OTHER
Intervention: Just-In-Time Adaptive Intervention
Description: Participants will be exposed to a new innovative app to test.
Study: NCT06404515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Group Counseling
Description: Group counseling for women via telehealth to provide educational materials about atherosclerotic heart disease and provide information about risk factors and modification of risk factors. Women then have an opportunity to discuss / ask questions.
Study: NCT05911672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRICE
Description: Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRICE
Description: Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
Study: NCT04826835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Description: Participants will:~* Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~* Practice six sessions of home-based exercise (three times per week for two weeks);~* Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~* Receive usual care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: Participants will:~* Receive four recorded health education talks (twice per week for two weeks)~* Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~* Receive usual care.
Study: NCT06549881

Intervention type: PROCEDURE
Intervention: emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
Description: emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
Study: NCT05177692

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vguard
Description: VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
Study: NCT05373030

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant adenovirus type-5-vectored COVID-19 vaccine
Description: One dose COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus type-5-vectored COVID-19 vaccine
Description: One dose COVID-19 vaccine
Study: NCT05545085

Intervention type: DEVICE
Intervention: Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device
Description: Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
Study: NCT05682274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial restoration approach combined with CAF+CTG
Description: The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial restoration approach combined with CAF+CTG
Description: The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
Study: NCT06154720

Intervention type: DRUG
Intervention: Antibiotics
Description: After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
Study: NCT06327360

Intervention type: OTHER
Intervention: Psychological questionnaires
Description: The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.

Intervention type: OTHER
Intervention: Psychological questionnaires
Description: The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.

Intervention type: OTHER
Intervention: Psychological questionnaires
Description: The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
Study: NCT05933694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-powered Spirometry Interpretation Report
Description: A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified
Study: NCT06532058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD107 capsule，Venclexta and Azacitidine
Description: QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD107 capsule，Venclexta and Azacitidine
Description: QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）
Study: NCT05068479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral Laser Scleral Microporation procedure
Description: Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral Laser Scleral Microporation procedure
Description: Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
Study: NCT05434585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABO1009-DP
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABO-CoV.617.2
Description: Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05495698

Intervention type: DRUG
Group type: OTHER
Intervention: single-inhaler triple therapy (Trimbow)
Description: Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.

Intervention type: DRUG
Group type: OTHER
Intervention: single-inhaler triple therapy (Trimbow)
Description: Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.

Intervention type: DEVICE
Group type: OTHER
Intervention: E-health application: Curavista app & FindAir e-device
Description: Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir

Intervention type: DRUG
Group type: OTHER
Intervention: multi-inhaler triple therapy (Qvar + Bevespi)
Description: Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.